CD6-ALCAM Pathway is Elevated in Patients with Severe Asthma

09/18/2020/by eallison

CD6 Is Highly Expressed In Fatal Asthma Patients and May Modulate Bronchomotor Tone

09/18/2020/by eallison

CD6 Is Expressed On Human Airway and Blood ILCs and Is Upregulated by Epithelial Alarmins IL-33 and TSLP

09/18/2020/by eallison

CD6-ALCAM Signaling Regulates Multiple Effector/Memory T Cell Functions

09/18/2020/by eallison

CD6 Modulation Ameliorates Immune Complex-Mediated Glomerulonephritis

09/18/2020/by eallison

Amelioration of Skin and Kidney Disease in a Spontaneous Murine Lupus Model via CD6 Modulation

09/18/2020/by eallison

Targeting the CD6-ALCAM Pathway to Prevent and Treat Graft vs Host Disease

09/18/2020/by eallison

EQUATE, a Phase 1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of a novel targeted anti-CD6 therapy, itolizumab, in subjects with newly diagnosed acute graft versus host disease

09/18/2020/by eallison

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation After In Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

09/18/2020/by eallison

Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation

09/18/2020/by eallison

CD6 Inhibition Prevents Skin and Kidney Disease in a Spontaneous Murine Model of SLE

09/18/2020/by eallison

Itolizumab May Have Broad Therapeutic Potential

01/23/2020/by eallison

The Role of T Cells in Health and Disease

01/21/2020/by David Anderson

The Role of CD6-ALCAM Signaling in Autoimmunity

01/16/2020/by David Anderson

The CD6-ALCAM Pathway Maybe a Predictive Biomarker in Patients with Lupus Nephritis

01/21/2020/by David Anderson

What Would You Say to an Individual Who is Newly Diagnosed with Lupus

01/21/2020/by David Anderson

The Pathogenesis of Lupus

01/21/2020/by David Anderson

Itolizumab Uniquely Modulates Both the Activity and Trafficking of T Effector Cells

01/21/2020/by David Anderson

Lupus is a Highly Heterogeneous Disease, No Two Patients Are Alike

01/21/2020/by David Anderson

The Need For a Personalized Approach in Treating Lupus Nephritis

01/21/2020/by David Anderson

The Path to Diagnosis and the Journey of Lupus

01/21/2020/by David Anderson

The Importance of Participating in Clinical Trials

01/16/2020/by David Anderson

Why it’s Important to Consider Clinical Trial Participation

01/16/2020/by David Anderson

Working Towards a Brighter Future for Individuals with Lupus and Lupus Nephritis

01/16/2020/by David Anderson

What is the Current Treatment Approach for Patients with Lupus Nephritis?

01/16/2020/by David Anderson

Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow

12/30/2019/by eallison

Relevance of CD6-mediated interactions in T cell activation and proliferation

12/30/2019/by eallison

Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells

12/30/2019/by eallison

CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction

12/30/2019/by eallison

A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation

12/30/2019/by eallison

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind randomized, placebo-controlled, phase-III study

12/30/2019/by eallison

Human Treg cells are characterized by low/negative CD6 expression

12/30/2019/by eallison

Itolizumab – a humanized, anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis

12/30/2019/by eallison

CD6 modulates thymocyte selection and peripheral T cell Homeostasis

12/30/2019/by eallison

Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance

12/30/2019/by eallison

Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis

12/30/2019/by eallison

T Cell Costimulation by CD6 is Dependent on Bivalent Binding of a GADS/SLP-76 Complex

12/30/2019/by eallison

Targeting CD6 for the treatment of experimental autoimmune uveitis

12/30/2019/by eallison

CD6 as a potential target for treating multiple sclerosis

12/30/2019/by eallison

T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab

12/30/2019/by eallison

The role of CD6 in autoimmune diseases

12/30/2019/by eallison

Activated Leukocyte Cell Adhesion Molecule Stimulates the T-Cell Response in Allergic Asthma

12/30/2019/by eallison

Failure of a T cell regulator: CD6 contributes to the aggravation of autoimmune inflammation

12/30/2019/by eallison

Activated leucocyte cell adhesion molecule (ALCAM/CD166) regulates T cell responses in a murine model of food allergy

12/30/2019/by eallison

Clinical and experimental evidence for targeting CD6 in immune-based disorders

12/30/2019/by eallison

Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease

12/30/2019/by David Anderson

The Clinical Implications of Lupus Nephritis

12/19/2019/by David Anderson